Trial · NCT04207918
A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer
NCT04207918, Phase 2, Completed, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer. Trials, record NCT04207918. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04207918
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer
- NCT number
- NCT04207918
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 55 participants, actual
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Conditions
- Esophageal Cancer, Chemoradiotherapy, Nimotuzumab, Unresectable Malignant Neoplasm
- Interventions
- Radiotherapy, Nimotuzumab, S-1
- First posted
- 2019-12-23
- Last updated
- 2024-05-16
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Local control rate | 1 year | |
| Secondary | Number of Participants with acute toxicities | 2-3 months | Acute toxicities are evaluated by NCI-CTC version 5.0 |
| Secondary | R0 resection rate | 2-3 months | The surgical procedure was radical esophagectomy after neoadjuvant therapy. |
| Secondary | Pathological response rate | 2-3 months | Pathological response were classified into five grades according to Mandard Tumor Regression Grade. |
| Secondary | Tumor Response rate | 2-3 months | |
| Secondary | Incidence of perioperative complications | 2-3 months | During hospital stay and within the first 30 days after completion of surgery. |
| Secondary | Overall survival | 1 year, 2 year | |
| Secondary | Progression free survival | 1 year, 2 year | |
| Secondary | Texture analysis of CT and/or MRI simulation in predicting tumor response rate and prognosis | 1 year, 2 year | |
| Secondary | ctDNA in predicting tumor response rate and prognosis | 1 year, 2 year |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04207918
GET https://conductscience.org/api/trials/v1/NCT04207918/registered